|
 At the turn of the year, STADA's owners Cinven and Bain Capital are setting the course for the future. No decision has yet been taken; various options are under consideration, including an initial public offering (IPO). In the event of an IPO, the board of directors will become the top leadership body of the German healthcare company and Andreas Fibig will assume the role of the independent chairman of STADA’s board of directors. With Andreas Fibig, STADA has secured an internationally experienced top manager with outstanding expertise in the pharmaceutical and consumer healthcare sectors.
The 62-year-old former chief executive officer (CEO) of International Flavours & Fragrances Inc. would become the independent chairman of STADA's board of directors.
“Andreas Fibig is an excellent choice as our candidate for the position of chairman of the board of directors of STADA. His global experience and outstanding expertise, especially in the healthcare sector, would help us enormously. Andreas shares our ‘Culture drives Performance’ mindset. I look forward to working with him,” commented STADA CEO Peter Goldschmidt.
“I am very honoured to assume the role of chairman of the board of directors at STADA in the event of an IPO. With its broad and strong product portfolio, STADA is one of the fastest-growing Consumer Healthcare companies worldwide and a major player as well in generics and specialty pharmaceuticals. I am particularly impressed by the growth-oriented corporate culture under the leadership of Peter Goldschmidt and his team,” said Andreas Fibig.
Fibig spent 10 years with International Flavours & Fragrances, an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S, where he is an independent director and member of the research and development committee. He also serves as a director in the Board of ExlService Holdings, a leading global data analytics and digital operations and solutions company.
The board of directors will be established at STADA's future listed Group holding company, which will be incorporated under Dutch law, but based in Germany. It will compromise of the chief executive officer and the chief financial officer of STADA as executive directors and seven further directors, including the chairman, with supervisory functions (non-executive directors).
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma.
|